Gao Peng, Wu Xian, Zhang Fu-Hua, Qiao Zhi-Li, Yang Li-Jie
Department of Emergency.
Department of General Medicine, Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, China.
Medicine (Baltimore). 2020 Jun 26;99(26):e20663. doi: 10.1097/MD.0000000000020663.
This study will assess the efficacy and safety of Shenmai injection (SMI) for the treatment of chronic heart failure (CHF).
The following electronic bibliographic databases will be searched from inception to the March 25, 2020 without language and publication time limitations: MEDLINE, PUBMED, Cochrane Library, Web of Science, Scopus, WANGFANG, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All randomized controlled trials related to the SMI for patients with CHF will be included. All study selection, data extraction, and study quality will be carried out by 2 reviewers. Any disagreements will be solved by a third reviewer through discussion. RevMan 5.3 software will be used for data synthesis and data analysis.
This study will summarize the present evidence of SMI for the treatment of patients with CHF.
The findings of this study will determine whether SMI is effective and safety for the treatment of CHF or not.
INPLASY202050029.
本研究将评估参麦注射液（SMI）治疗慢性心力衰竭（CHF）的疗效和安全性。
将检索以下电子文献数据库，检索时间从建库至2020年3月25日，无语言和发表时间限制：MEDLINE、PUBMED、Cochrane图书馆、科学网、Scopus、万方、中国生物医学文献数据库和中国知网。将纳入所有与参麦注射液治疗CHF患者相关的随机对照试验。所有研究筛选、数据提取和研究质量评估将由2名评审员进行。任何分歧将由第三名评审员通过讨论解决。将使用RevMan 5.3软件进行数据合成和数据分析。
本研究将总结目前参麦注射液治疗CHF患者的证据。
本研究结果将确定参麦注射液治疗CHF是否有效和安全。
INPLASY202050029。
